137 related articles for article (PubMed ID: 20626043)
101. Decreasing incidence of dialysis in older patients in The Netherlands as compared with other European countries: an international perspective.
van Oevelen M; Abrahams AC; Hoekstra T; Ten Dam MAGJ; Kramer A; Jager KJ; Ocak G; van Buren M; Bos WJW
Clin Kidney J; 2023 Jul; 16(7):1149-1159. PubMed ID: 37398682
[TBL] [Abstract][Full Text] [Related]
102. Epidemiology of Cervical Cancer in the Caribbean.
Scott-Williams J; Hosein A; Akpaka P; Adidam Venkata CR
Cureus; 2023 Nov; 15(11):e48198. PubMed ID: 38054120
[TBL] [Abstract][Full Text] [Related]
103. Recent changes in trends of mortality from cervical cancer in Southeastern Brazil.
Luizaga CTM; Jardim BC; Wünsch Filho V; Eluf Neto J; Silva GAE
Rev Saude Publica; 2023; 57():25. PubMed ID: 37075421
[TBL] [Abstract][Full Text] [Related]
104. Time Trends for Incidence and Net Survival of Cervical Cancer in Sweden 1960-2014-A Nationwide Population-Based Study.
Sundqvist A; Moberg L; Dickman PW; Högberg T; Borgfeldt C
Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1572-1581. PubMed ID: 35654420
[TBL] [Abstract][Full Text] [Related]
105. Efficacy of Raman Spectroscopy in the Diagnosis of Uterine Cervical Neoplasms: A Meta-Analysis.
Shen ZW; Zhang LJ; Shen ZY; Zhang ZF; Xu F; Zhang X; Li R; Xiao Z
Front Med (Lausanne); 2022; 9():828346. PubMed ID: 35602511
[TBL] [Abstract][Full Text] [Related]
106. A sandwich SERS immunoassay platform based on a single-layer Au-Ag nanobox array substrate for simultaneous detection of SCCA and survivin in serum of patients with cervical lesions.
Liu Y; Ran M; Sun Y; Fan Y; Wang J; Cao X; Lu D
RSC Adv; 2021 Nov; 11(58):36734-36747. PubMed ID: 35494344
[TBL] [Abstract][Full Text] [Related]
107. Prospective detection of cervical dysplasia with scanning angle-resolved low coherence interferometry.
Kendall WY; Ho D; Chu K; Zinaman M; Wieland D; Moragne K; Wax A
Biomed Opt Express; 2020 Sep; 11(9):5197-5211. PubMed ID: 33014608
[TBL] [Abstract][Full Text] [Related]
108. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.
Arbyn M; Weiderpass E; Bruni L; de Sanjosé S; Saraiya M; Ferlay J; Bray F
Lancet Glob Health; 2020 Feb; 8(2):e191-e203. PubMed ID: 31812369
[TBL] [Abstract][Full Text] [Related]
109. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
[TBL] [Abstract][Full Text] [Related]
110. Cytomorphological characteristics of glassy cell carcinoma of the uterine cervix: histopathological correlation and human papillomavirus genotyping.
Jung YY; Nahm JH; Kim HS
Oncotarget; 2016 Nov; 7(45):74152-74161. PubMed ID: 27708230
[TBL] [Abstract][Full Text] [Related]
111. Distribution of Carcinogenic Human Papillomavirus Genotypes and Association to Cervical Lesions among Women in Fez (Morocco).
Souho T; El Fatemi H; Karim S; El Rhazi K; Bouchikhi C; Banani A; Melhouf MA; Benlemlih M; Bennani B
PLoS One; 2016; 11(1):e0146246. PubMed ID: 26731415
[TBL] [Abstract][Full Text] [Related]
112. The end of the decline in cervical cancer mortality in Spain: trends across the period 1981-2012.
Cervantes-Amat M; López-Abente G; Aragonés N; Pollán M; Pastor-Barriuso R; Pérez-Gómez B
BMC Cancer; 2015 Apr; 15():287. PubMed ID: 25886170
[TBL] [Abstract][Full Text] [Related]
113. A population-based evaluation of cervical screening in the United States: 2008-2011.
Cuzick J; Myers O; Hunt WC; Robertson M; Joste NE; Castle PE; Benard VB; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):765-73. PubMed ID: 24302677
[TBL] [Abstract][Full Text] [Related]
114. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005.
Hoffmann R; Plug I; McKee M; Khoshaba B; Westerling R; Looman C; Rey G; Jougla E; Lang K; Pärna K; Mackenbach JP
Int J Public Health; 2014 Apr; 59(2):341-50. PubMed ID: 23989709
[TBL] [Abstract][Full Text] [Related]
115. Recommendations on screening for cervical cancer.
Dickinson J; Tsakonas E; Conner Gorber S; Lewin G; Shaw E; Singh H; Joffres M; Birtwhistle R; Tonelli M; Mai V; McLachlin M;
CMAJ; 2013 Jan; 185(1):35-45. PubMed ID: 23297138
[No Abstract] [Full Text] [Related]
116. Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached?
de Kok IM; van der Aa MA; van Ballegooijen M; Siesling S; Karim-Kos HE; van Kemenade FJ; Coebergh JW;
Int J Cancer; 2011 May; 128(9):2174-81. PubMed ID: 20626043
[TBL] [Abstract][Full Text] [Related]
117. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013.
van der Horst J; Siebers AG; Bulten J; Massuger LF; de Kok IM
Cancer Med; 2017 Feb; 6(2):416-423. PubMed ID: 28102052
[TBL] [Abstract][Full Text] [Related]
118. Exploring the trend of increased cervical intraepithelial neoplasia detection rates in the Netherlands.
Rozemeijer K; van Kemenade FJ; Penning C; Matthijsse SM; Naber SK; van Rosmalen J; van Ballegooijen M; de Kok IM
J Med Screen; 2015 Sep; 22(3):144-50. PubMed ID: 25977375
[TBL] [Abstract][Full Text] [Related]
119. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands.
van der Aa MA; Pukkala E; Coebergh JW; Anttila A; Siesling S
Int J Cancer; 2008 Apr; 122(8):1854-8. PubMed ID: 18067129
[TBL] [Abstract][Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
